The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
How I treat extramedullary acute myeloid leukemia
Open accessAbstract
Extramedullary (EM) manifestations of acute leukemia include a wide variety of clinically significant phenomena that often pose therapeutic dilemmas. Myeloid sarcoma (MS) and leukemia cutis (LC) represent 2 well-known EM manifestations with a range of clinical presentations. MS (also known as granulocytic sarcoma or chloroma) is a rare EM tumor of immature myeloid cells. LC specifically refers to the infiltration of the epidermis, dermis, or subcutis by neoplastic leukocytes (leukemia cells), resulting in clinically identifiable cutaneous lesions. The molecular mechanisms underlying EM involvement are not well defined, but recent immunophenotyping, cytogenetic, and molecular analysis are beginning to provide some understanding. Certain cytogenetic abnormalities are associated with increased risk of EM involvement, potentially through altering tissue-homing pathways. The prognostic significance of EM involvement is not fully understood. Therefore, it has been difficult to define the optimal treatment of patients with MS or LC. The timing of EM development at presentation versus relapse, involvement of the marrow, and AML risk classification help to determine our approach to treatment of EM disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationFirminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Self-citationTumors of the hematopoietic system
Rappaport, H. (1966) · University of Michigan Library Repository · Cited by 884
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
Pileri, S. A., Ascani, S., Cox, M. C., Campidelli, C., Bacci, F., Piccioli, M., Piccaluga, P. P., Agostinelli, C., Asioli, S., Novero, D., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404491 · Cited by 720
Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682
Grignani, F., Ferrucci, P. F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., Mencarelli, A., Grignani, F., Peschle, C., Nicoletti, I., et al. (1993) · Cell · doi:10.1016/0092-8674(93)80044-f · Cited by 583
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells
Fuhlbrigge, R. C., Kieffer, J. D., Armerding, D., & Kupper, T. S. (1997) · Nature · doi:10.1038/40166 · Cited by 577
Metadata
- Authors
- Bakst, R. L., Tallman, M. S., Douer, D., & Yahalom, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-10-06
- Volume
- 118
- Issue
- 14
- Pages
- 3785-3793
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2047737345
- Cited by
- 503
- References
- 25
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How I treat extramedullary acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2011-04-347229
- The paper
- Bakst, R. L., Tallman, M. S., Douer, D., & Yahalom, J. (2011). How I treat extramedullary acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2011-04-347229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
